



PTO/SB/08a/b (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/506729
				Filing Date	September 3, 2004
				First Named Inventor	Andrew Stocker
				Art Unit	4615-1626
Examiner Name	Not Yet Assigned M. BARKER				
Sheet	1	of	3	Attorney Docket Number	ASZD-P01-664


U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
MB	AA	US-2004/0002495-A1	01-01-2004	Philip Sher	
MB	AB	US-3,706,810	12-19-1972	AMERICAN CYANAMID	
MB	AC	US-4,599,198	07-08-1986	DENNIS J. HOOVER	
MB	AD	US-4,668,769	05-26-1987	DENNIS J. HOOVER	
MB	AE	US-4,720,503	01-19-1988	BRUCE E. WITZEL	
MB	AF	US-4,751,231	06-14-1988	WASYL HALCZENKO	
MB	AG	US-4,786,641	11-22-1988	SIEGFRIED GOLDMANN	
MB	AH	US-4,794,120	12-27-1988	PHILIPPE MANOURY	
MB	AI	US-5,863,903	01-26-1999	KARSTEN LUNDGREN	
MB	AJ	US-5,998,463	12-07-1999	BERNARD HULIN	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
MB	BA	WO-00/42213	07-20-2000	The Research Foundation of State University of New York		
MB	BB	WO-00/47206	08-17-2000	Novo Nordisk		
MB	BC	WO-01/05954	01-25-2001	Isis Pharmaceuticals, Inc.		
MB	BD	WO-01/23347	04-05-2001	Novo Nordisk		
MB	BE	WO-01/32654	05-10-2001	Societe de Conseils de Recherches et D'Applications Scientifiques		
MB	BF	WO-01/52825	07-26-2001	Novartis-Erfindungen Verwaltungsgesellschaft M.B.H.		
MB	BG	WO-01/68055	09-20-2001	Pfizer Products Inc.		
MB	BH	WO-01/68092	09-20-2001	Pfizer Products Inc.		
MB	BI	WO-01/68603	09-20-2001	Bristol-Myers Squibb Co.		
MB	BJ	WO-01/94300	12-13-2001	Aventis Pharma Deutschland		
MB	BK	WO-01/96311	12-20-2001	Bristol-Myers Squibb Company		
MB	BL	WO-01/96347	12-20-2001	Bristol-Myers Squibb Company		
MB	BM	WO-02/080844	10-17-2002	Genzyme Corporation		
MB	BN	WO-02/096864	12-05-2002	Aventis Pharma Deutschland GmbH		
MB	BO	WO-02/098348	12-12-2002	Eli Lilly and Company		
MB	BP	WO-02/26714	04-04-2002	Takeda Chemical Industries, Ltd.		
MB	BQ	WO-02/34718	05-02-2002	Richter Gedeon Vegyeszeti Gyar Rt.		
MB	BR	WO-03/037864	05-08-2003	Japan Tobacco Inc.		
MB	BS	EP-0846464	06-10-1998	Pfizer Inc.		
MB	BT	EP-0884050	12-16-1998	Novo Nordisk		
MB	BU	EP-0978279	02-09-2000	Pfizer Products Inc.		
MB	BV	EP-1088824	01-07-2004	Pfizer Products Inc.		
MB	BW	EP-1125580	08-22-2001	Pfizer Products Inc.		
MB	BX	EP-1134213	09-19-2001	Pfizer Inc.		
MB	BY	EP-1136071	09-26-2001	Pfizer Products Inc.		
Examiner Signature	M. P. B.			Date Considered	3-15-06	

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete If Known	
				Application Number	10/506729
				Filing Date	September 3, 2004
				First Named Inventor	Andrew Stocker
				Art Unit	1615 / 1626
				Examiner Name	Not Yet Assigned M. BARBER
Sheet	2	of	3	Attorney Docket Number	ASZD-P01-664

MB	BZ	EP-1145717	05-12-2004	Pfizer Products Inc.		
MB	BA1	EP-1149580	02-21-2001	Pfizer Products Inc.		
MB	BB1	EP-1177791	07-27-2001	Pfizer Products Inc.		
MB	BC1	ES-2081747	03-01-1996	Esteve Labor DR		
MB	BD1	DE-4445968	06-27-1996	Bayer AG		
MB	BE1	WO-93/25574	12-23-1993	Pfizer Inc.		
MB	BF1	WO-95/24391	09-14-1995	Novo Nordisk		
MB	BG1	WO-96/39384	12-12-1996	Pfizer, Inc.		
MB	BH1	WO-96/39385	12-12-1996	Pfizer Inc.		
MB	BI1	WO-97/09040	03-13-1997	Novo Nordisk		
MB	BJ1	WO-97/31901	09-04-1997	Mikael Bols		
MB	BK1	WO-97/45425	12-04-1997	Fujisawa Pharmaceutical Co., Ltd.		
MB	BL1	WO-98/27108	06-25-1998	Fuji-Sawa Pharmaceutical Co., Ltd.		
MB	BM1	WO-98/40353	09-17-1998	Novo Nordisk		
MB	BN1	WO-98/50359	11-12-1998	Novo Nordisk		
MB	BO1	WO-99/26659	06-03-1999	Pfizer Products Inc.		
MB	BP1	WO-99/36393	07-22-1999	Tanabe Seiyaku Co., Ltd.		
MB	BQ1	JP 2001 089368				
MB	BR1	DD 200740	06-08-1983	Gewald		
MB	BS1	EP 697403	02-21-1996	Sanofi		
MB	BT1	JP 2001 206856	07-31-2001	Pfizer Prod. Inc.		
MB	BU1	JP 021247565	05-14-1990	Hanawa Netsuden Kinzoku KK		
MB	BV1	JP 04179949	06-26-1992	Toray Ind. Inc.		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				T ²
MB	CA	Birch, A., et al., "Novel Thienopyrrole Glycogen Phosphorylase Inhibitors: In Vitro SAR and Crystallographic Studies," Poster, AstraZeneca UK, CVGI Research, Mereside, Alderley Park, Macclesfield, Cheshire.				
MB	CB	Crochet, R.A., et al., "Synthesis of Substituted Thieno[2,3-b] pyrroles," Vol. 11, 143-150 (April 1974).				
MB	CC	Freeman, S., et al., "Effect of Glucose on Rat and Human Liver Glycogen Phosphorylase Activity and Potency of a Glycogen Phosphorylase Inhibitor," Diabetes, 52, Supp., 1470-P, A340.				
MB	CD	Hartman, G.D., et al., "The Synthesis of 5-Alkylaminomethylthieno[2,3-b]Pyrrole-5-Sulfonamides," Heterocycles, 29(10):1943-1949 (1989).				
MB	CE	Hoover, D.J., et al., "Indole-2-carboxamide Inhibitors of Human Liver Glycogen Phosphorylase," J. Med. Chem., 41:2934-2938 (1998).				
MB	CF	Hudson, S., et al., "The effect of a glycogen phosphorylase inhibitor upon muscle fatigue in anaesthetised rats," J. Physiol., 539:52-53 (2002).				
MB	CG	Jakobsen, P., et al., "Iminosugars: Potential Inhibitors of Liver Glycogen Phosphorylase."				
Examiner Signature					Date Considered	3-15-06

Substitute for form 1449A/B/PTO				Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/506729
				Filing Date	September 3, 2004
				First Named Inventor	Andrew Stocker
				Art Unit	4615 162b
				Examiner Name	Not Yet Assigned / M. BARKER
Sheet	3	of	3	Attorney Docket Number	ASZD-P01-664

Not
Submitted

		Bioorganic Med. Chem., 9:733-744 (2001).	
MB	CH	Martin, W.H., et al., "Discovery of a human liver glycogen phosphorylase inhibitor that lowers blood glucose in vivo," PNAS, 95:1776-1781 (Feb. 1998).	
MB	CI	McCormack, J.G., et al., "Pharmacological Approaches to Inhibit Endogenous Glucose Production as a Means of Anti-diabetic Therapy," Curr. Pharmaceutical Design, 7:1451-1474 (2001).	
MB	CJ	Oikonomakos, N.G., et al., "Allosteric inhibition of glycogen phosphorylase alpha by the potential antidiabetic drug 3-isopropyl 4-(2-chlorophenyl)-1,4-dihydro-1-ethyl-2-methyl-pyridine-3,5,6-tricarboxylate," Protein Sci., 8:1930-1945 (1999).	
MB	CK	Rath, V.L. et al., "Activation of Human Liver Glycogen Phosphorylase by Alteration of the Secondary Structure and Packing of the Catalytic Core," Mol. Cell, 6:139-148 (July 2000).	
MB	CL	Rosauer, K.G., et al., "Novel, 3,4-Dihydroquinolin-2(1H)-one Inhibitors of Human Glycogen Phosphorylase a," Bioorganic & Medicinal Chemistry Letters, 13:4385-4388 (2003).	
MB	CM	Soman, G., et al., "Aromatic Compounds as Allosteric Inhibitors of Glycogen Phosphorylase beta," Biochimica et Biophysica Acta, 358:359-362 (1974).	
MB	CN	Soman, G., et al., "The Nature of the Binding Site for Aromatic Compounds in Glycogen Phosphorylase beta," Biochem. J., 147:369-371 (1975).	
MB	CO	Teague, J., "Mobilisation of Tissue Glycogen Following Inhibition of Glycogen Phosphorylase in fa/fa Rat," Diabetes, 53, Supp. 1, A365, 1521-P	
MB	CP	Treadway, J.L., et al., "Glycogen phosphorylase inhibitors for treatment of type 2 diabetes mellitus," Exp. Opin. Invest. Drugs, 10(3):439-454 (2001).	
MB	CQ	Turnbull, A., et al., "Pharmacological Inhibition of Glycogen Phosphorylase (GP) Lowers Plasma Glucose in Rat Models of Type 2 Diabetes," Diabetes, 52, Supp., 1485-P, A343.	
MB	CR	Venkatarangan, P., et al., "Prediction of Ligand-REceptor Binding Thermodynamics by Free Energy Force Field Three-Dimensional Quantitative Structure-Activity Relationship Analysis: Applications to a Set of Glucose Analogue Inhibitors of Glycogen Phosphorylase," J. Med. Chem., 42:2169-2179 (1999).	
MB	CS	Vertigan, H., "Impact of cell glycogen content on modulation of hepatocyte glucose metabolism by pharmacological agents," Diabetes, 47, Supp., 589, A214.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	M. P. BL	Date Considered	3.15.06
--------------------	----------	-----------------	---------